<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947349</url>
  </required_header>
  <id_info>
    <org_study_id>1220.14</org_study_id>
    <nct_id>NCT00947349</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients</brief_title>
  <official_title>Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naïve and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current Standard of Care (SOC) for chronic HCV infection, which is pegylated
      interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is
      effective in only part of the patients and is often associated with severe adverse effects
      leading to discontinuation of treatment and dose modifications.

      A number of compounds with direct activity are currently under clinical development, incl.
      BI 201335. BI 201335 works by preventing the Hepatitis C virus from replicating by binding
      to the HCV protease (enzyme). The main purpose of this clinical trial with BI 201335 is to
      see how well BI 201335 works and how safe BI 201335 is to use daily in combination with
      PegIFN and RBV in HCV infected patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Investigator Defined Drug-related Adverse Events in Triple Combination Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug-related AEs were defined as those whose causal relationship with any one of the investigational products was considered by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Triple Combination Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency of patients with possible clinically significant abnormalities or clinically significant laboratory test value changes over time in triple combination therapy for treatment naive patients and treatment experienced patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Tolerability in Triple Combination Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>An assessment of tolerability for the safety of the triple combination therapy with BI 201335 NA, PegIFN α -2a and RBV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Week 2 Virological Response (W2VR)</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients satisfying W2VR (plasma HCV RNA (Hepatitis C Virus Ribonucleic acid) level below the limit of quantification (BLQ))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 4 Virological Response (W4VR)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients satisfying W4VR (plasma HCV RNA level below the limit of quantification (BLQ))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid Virological Response (RVR)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients satisfying RVR (plasma HCV RNA level below the limit of detection (BLD) at Week 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HCV Viral Load</measure>
    <time_frame>baseline and week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change form baseline in HCV viral load (log10) after 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 Virologic Response</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with HCV viral load reduction &gt;= 2 log10 at Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Virological Response (EVR)</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with reduction &gt;= 2 log10 in plasma HCV RNA level at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Early Virological Response (cEVR)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with plasma HCV RNA level BLD at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (ETR)</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with plasma HCV RNA level BLD at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response (SVR)</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with plasma HCV RNA level BLD 24 weeks after treatment completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Investigator Defined Drug-related Adverse Events in Standard of Care (SOC) With PegIFN α-2a and RBV</measure>
    <time_frame>44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug-related AEs in SOC treatment period were defined as those whose causal relationship with any one of the investigational products was considered by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Standard of Care (SOC) With PegIFN α-2a and RBV</measure>
    <time_frame>44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency of patients with possible clinically significant abnormalities or clinically significant laboratory test value changes over time in SOC period for treatment naive patients and treatment experienced patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tolerability in Standard of Care (SOC) With PegIFN α -2a and RBV</measure>
    <time_frame>44 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>An assessment of tolerability for the safety of the SOC with PegIFN alfa-2a and RBV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the curve (AUC) concentration after the first dose of BI 201335 ZW</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum concentration of BI 201335 ZW after multiple oral admin. of BI 201335 NA with RBV and PegIFN alfa-2a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss of BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC at steady state after 4 weeks combination of the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum concentration of BI 201335 ZW at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 for Ribavirin (RBV)</measure>
    <time_frame>-0:10, 1,2,3,4,5,6,8,10,11:50, 23:50 hours on the first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration curve of RBV after the first dose of placebo or BI 201335 NA with with RBV and PegIFN alfa-2a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of RBV</measure>
    <time_frame>-0:10, 1,2,3,4,5,6,8,10,11:50, 23:50 hours on the first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum Plasma concentration of RBV after multiple oral admin. of placebo with RBV and PegIFN alfa-2a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss of RBV</measure>
    <time_frame>-0:10, 1,2,3,4,5,6,8,10,11:50, 23:50 hours on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration curve of RBV after the multiple oral administration of BI 201335 NA (or placebo) with RBV and PegIFN alfa-2a at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of RBV</measure>
    <time_frame>-0:10, 1,2,3,4,5,6,8,10,11:50, 23:50 hours on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum Plasma concentration of RBV after multiple oral admin. of BI 201335 NA (or placebo) with RBV and PegIFN alfa-2a at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to maximum plasma concentration (tmax) of BI 201335 ZW after the first dose of BI 201335 NA with RBV and PegIFN alfa-2a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for RBV</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to maximum plasma concentration (tmax) of RBV after the first dose of BI 201335 NA with RBV and PegIFN alfa-2a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, ss for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from last dosing to the maximum plasma concentration (tmax) of BI 201335 ZW after the last dose of BI 201335 NA with RBV and PegIFN alfa-2a at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, ss for RBV</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to the maximum plasma concentration (tmax) of RBV after the last dose of BI 201335 NA with RBV and PegIFN alfa-2a at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>terminal half-life of the analyte in plasma at steady state (t1/2,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum concentration of the analyte (BI 201335 ZW) in plasma over the dosing interval at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss for RBV</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minimum concentration of the analyte (RBV) in plasma over the dosing interval at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>average plasma concentration (Cavg) of BI 201335 ZW</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg for RBV</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>average plasma concentration (Cavg) of RBV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss for BI 201335 ZW</measure>
    <time_frame>10 minutes before drug administration and 1 hour (h),2h,3h,4h,5h,6h,8h,10h,11:50h, 23:50h on the last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>apparent clearance of the analyte (BI 201335 ZW) in plasma at steady state (CL/F,ss) following multiple oral administration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>BI 201335 NA low TN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 201335 NA high TN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 201335 NA high TE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Treatment Naive (TN) Patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (RBV)</intervention_name>
    <description>ribavirin (RBV)</description>
    <arm_group_label>BI 201335 NA high TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon (PegIFN) alfa-2a</intervention_name>
    <description>pegylated interferon (PegIFN) alfa-2a</description>
    <arm_group_label>BI 201335 NA low TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon (PegIFN) alfa-2a</intervention_name>
    <description>pegylated interferon (PegIFN) alfa-2a</description>
    <arm_group_label>BI 201335 NA high TE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (RBV)</intervention_name>
    <description>ribavirin (RBV)</description>
    <arm_group_label>BI 201335 NA high TE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA low placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BI 201335 NA low TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon (PegIFN) alfa-2a</intervention_name>
    <description>pegylated interferon (PegIFN) alfa-2a</description>
    <arm_group_label>BI 201335 NA high TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (RBV)</intervention_name>
    <description>ribavirin (RBV)</description>
    <arm_group_label>BI 201335 NA low TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA high</intervention_name>
    <description>BI 201335 NA high</description>
    <arm_group_label>BI 201335 NA high TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA low</intervention_name>
    <description>BI 201335 NA</description>
    <arm_group_label>BI 201335 NA low TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA high placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>BI 201335 NA high TN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA high</intervention_name>
    <description>BI 201335 NA high</description>
    <arm_group_label>BI 201335 NA high TE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo in Treatment Naive (TN) Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  chronic HCV genotype-1;

          -  high viral load

        Exclusion criteria:

          -  Mixed genotype (1/2, 1/3, or 1/4), diagnosed by genotypic testing at screening

          -  Previous treatment with protease inhibitor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.14.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurashiki, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.14.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.14.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishinomiya, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 3, 2015</lastchanged_date>
  <firstreceived_date>July 21, 2009</firstreceived_date>
  <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
